| 000 | 01766 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250518004531.0 | ||
| 264 | 0 | _c20191014 | |
| 008 | 201910s 0 0 eng d | ||
| 022 | _a1573-8744 | ||
| 024 | 7 |
_a10.1007/s10928-018-9609-6 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBiliouris, Konstantinos | |
| 245 | 0 | 0 |
_aA pre-clinical quantitative model predicts the pharmacokinetics/pharmacodynamics of an anti-BDCA2 monoclonal antibody in humans. _h[electronic resource] |
| 260 |
_bJournal of pharmacokinetics and pharmacodynamics _c12 2018 |
||
| 300 |
_a817-827 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xpharmacology |
| 650 | 0 | 4 | _aBody Weight |
| 650 | 0 | 4 | _aComputer Simulation |
| 650 | 0 | 4 | _aDrug Evaluation, Preclinical |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunoglobulin G |
| 650 | 0 | 4 |
_aLectins, C-Type _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aLupus Erythematosus, Cutaneous _xdrug therapy |
| 650 | 0 | 4 |
_aLupus Erythematosus, Systemic _xdrug therapy |
| 650 | 0 | 4 | _aMacaca fascicularis |
| 650 | 0 | 4 |
_aMembrane Glycoproteins _xantagonists & inhibitors |
| 650 | 0 | 4 | _aModels, Biological |
| 650 | 0 | 4 |
_aReceptors, Immunologic _xantagonists & inhibitors |
| 700 | 1 | _aNestorov, Ivan | |
| 700 | 1 | _aNaik, Himanshu | |
| 700 | 1 | _aDai, David | |
| 700 | 1 | _aXiao, Guangqing | |
| 700 | 1 | _aWang, Qin | |
| 700 | 1 | _aPellerin, Alex | |
| 700 | 1 | _aRabah, Dania | |
| 700 | 1 | _aLesko, Lawrence J | |
| 700 | 1 | _aTrame, Mirjam N | |
| 773 | 0 |
_tJournal of pharmacokinetics and pharmacodynamics _gvol. 45 _gno. 6 _gp. 817-827 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s10928-018-9609-6 _zAvailable from publisher's website |
| 999 |
_c28994631 _d28994631 |
||